Moreover, this IGF-Trap had an enhanced therapeutic profile, as evaluated in an experimental colon carcinoma liver metastasis model and was superior to a ligand binding antibody used under the same conditions (Figure 4). This evidence concerns the gene IGF1 and colon carcinoma.